Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke

NCT02730455 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02730455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02730455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
July 18, 2016
Completion date
November 20, 2017
Enrollment
277 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke